ETFIS Series Trust I NPORTP Virtus LifeSci Biotech Clinical Trials ETF (Jan 2024 report)

Schedule of Investments - Virtus LifeSci Biotech Clinical Trials ETF

January 31, 2024 (unaudited)

Security Description	Shares		Value

COMMON STOCKS - 97.8%
Health Care - 97.8%
4D Molecular Therapeutics, Inc.*		4,941	$	85,232
89bio, Inc.*		7,612		75,359
AbCellera Biologics, Inc. (Canada)*		14,975		76,522
ACELYRIN, Inc.*		11,272		85,893
Agenus, Inc.*		107,808		71,929
Akero Therapeutics, Inc.*		3,677		79,460
Alector, Inc.*		10,258		61,138
Allakos, Inc.*		26,052		33,086
Allogene Therapeutics, Inc.*		30,282		106,593
Alpine Immune Sciences, Inc.*		4,347		115,674
ALX Oncology Holdings, Inc.*		6,222		89,659
Ambrx Biopharma, Inc.*		6,097		169,497
AnaptysBio, Inc.*		4,310		101,716
Apogee Therapeutics, Inc.*⁽¹⁾		3,531		118,289
Arcellx, Inc.*		1,600		98,944
Arcturus Therapeutics Holdings, Inc.*		2,927		96,503
Arcus Biosciences, Inc.*		4,654		70,462
Ardelyx, Inc.*		14,149		123,521
Arrowhead Pharmaceuticals, Inc.*		2,875		92,288
Arvinas, Inc.*		2,300		95,450
Avidity Biosciences, Inc.*		10,219		124,978
Beam Therapeutics, Inc.*		2,755		67,222
Belite Bio, Inc.*⁽¹⁾⁽²⁾		1,858		80,693
Bicycle Therapeutics PLC (United Kingdom)*⁽²⁾		5,471		95,469
Biohaven Ltd.*		2,180		96,966
Biomea Fusion, Inc.*		5,840		105,587
Cabaletta Bio, Inc.*		3,995		81,818
Caribou Biosciences, Inc.*		13,300		81,529
Cassava Sciences, Inc.*⁽¹⁾		2,726		65,288
Celldex Therapeutics, Inc.*		2,270		79,949
Cogent Biosciences, Inc.*		16,545		73,294
Compass Pathways PLC (United Kingdom)*⁽²⁾		10,630		119,800
Crinetics Pharmaceuticals, Inc.*		2,353		85,837
Cullinan Oncology, Inc.*		9,643		145,995
CureVac NV (Germany)*⁽¹⁾		14,198		50,971
Cymabay Therapeutics, Inc.*		3,792		89,150
Cytokinetics, Inc.*		2,242		175,167
Day One Biopharmaceuticals, Inc.*		5,754		86,598
Denali Therapeutics, Inc.*		3,540		56,675
Disc Medicine, Inc.*		1,408		92,576
Dynavax Technologies Corp.*		6,048		78,140
Dyne Therapeutics, Inc.*		6,943		148,580
Editas Medicine, Inc.*		7,571		53,224
Exscientia PLC (United Kingdom)*⁽¹⁾⁽²⁾		13,909		81,089
Geron Corp.*		37,133		68,325
Ideaya Biosciences, Inc.*		2,398		104,385
IGM Biosciences, Inc.*⁽¹⁾		12,625		132,815
Immatics NV (Germany)*		8,374		95,129
ImmunityBio, Inc.*⁽¹⁾		20,163		67,748
Immunovant, Inc.*		1,927		70,162
Inhibrx, Inc.*		2,980		114,819
Intellia Therapeutics, Inc.*		2,576		61,360
Iovance Biotherapeutics, Inc.*		10,644		82,278
iTeos Therapeutics, Inc.*		7,619		75,809
Karuna Therapeutics, Inc.*		375		117,533
Keros Therapeutics, Inc.*		2,431		134,580
Krystal Biotech, Inc.*		706		78,543
Kura Oncology, Inc.*		6,867		138,301
Kymera Therapeutics, Inc.*		3,225		105,716
Liquidia Corp.*		11,257		143,864
Lyell Immunopharma, Inc.*		40,625		74,344
MacroGenics, Inc.*		8,814		126,040
Madrigal Pharmaceuticals, Inc.*		352		76,282
Merus NV (Netherlands)*		3,246		115,817
Mineralys Therapeutics, Inc.*		9,947		108,522
MoonLake Immunotherapeutics*		1,423		79,517
Morphic Holding, Inc.*		2,777		88,003
Neumora Therapeutics, Inc.*⁽¹⁾		5,609		83,574
Novavax, Inc.*⁽¹⁾		14,422		57,688
Nurix Therapeutics, Inc.*		9,179		72,514
Nuvalent, Inc. Class A*		1,039		78,102
Olema Pharmaceuticals, Inc.*		6,661		86,859
ORIC Pharmaceuticals, Inc.*		8,939		98,240
Phathom Pharmaceuticals, Inc.*		9,189		61,566
Pliant Therapeutics, Inc.*		4,894		87,700
Precigen, Inc.*		65,129		89,878
Protagonist Therapeutics, Inc.*		3,951		98,815
Prothena Corp. PLC (Ireland)*		2,103		59,704
RAPT Therapeutics, Inc.*		4,243		105,014
RayzeBio, Inc.*		3,086		191,641
Recursion Pharmaceuticals, Inc. Class A*		8,611		81,030
REGENXBIO, Inc.*		3,942		48,565
Relay Therapeutics, Inc.*		8,239		76,211
Replimune Group, Inc.*		10,576		82,070
REVOLUTION Medicines, Inc.*		3,138		87,080
Rocket Pharmaceuticals, Inc.*		2,902		83,374
Sana Biotechnology, Inc.*		20,567		112,913
Scholar Rock Holding Corp.*		4,421		61,673
Scilex Holding Co. (Singapore)*⁽³⁾		17,635		27,475
Soleno Therapeutics, Inc.*		2,207		102,294
Spyre Therapeutics, Inc.*		5,530		143,282
Structure Therapeutics, Inc.*⁽²⁾		1,400		61,068
Summit Therapeutics, Inc.*		31,085		121,853
Syndax Pharmaceuticals, Inc.*		4,128		84,583
Tango Therapeutics, Inc.*		8,054		94,635
Terns Pharmaceuticals, Inc.*		12,664		65,600
TG Therapeutics, Inc.*		4,559		74,038
uniQure NV (Netherlands)*		10,131		56,328
Vaxcyte, Inc.*		1,354		96,703
Vera Therapeutics, Inc.*		5,574		203,005
Verve Therapeutics, Inc.*		5,731		62,009
Viking Therapeutics, Inc.*		4,270		103,078
Vir Biotechnology, Inc.*		8,173		76,826
Viridian Therapeutics, Inc.*		4,243		81,678
Xencor, Inc.*		3,867		72,313
Xenon Pharmaceuticals, Inc. (Canada)*		1,990		89,988
Zentalis Pharmaceuticals, Inc.*		5,486		65,009
Zymeworks, Inc.*		9,098		98,622
Total Health Care				9,908,300
Total Common Stocks
(Cost $11,940,401)				9,908,300

Schedule of Investments - Virtus LifeSci Biotech Clinical Trials ETF (continued)

January 31, 2024 (unaudited)

Security Description	Shares		Value

SECURITIES LENDING COLLATERAL - 7.3%
Money Market Fund - 7.3%
Dreyfus Government Cash Management Fund, Institutional Shares, 5.22%⁽⁴⁾⁽⁵⁾
(Cost $733,438)		733,438	$	733,438

TOTAL INVESTMENTS - 105.1%
(Cost $12,673,839)				10,641,738
Liabilities in Excess of Other Assets - (5.1)%				(514,099	)
Net Assets - 100.0%			$	10,127,639

*	Non-income producing security.
(1)	All or a portion of the security was on loan. The aggregate market value of securities on loan was $1,691,070; total market value of collateral held by the Fund was $1,752,983. Market value of the collateral held includes non-cash U.S. Treasury securities having a value of $1,019,546.
(2)	American Depositary Receipts.
(3)	Restricted security. See Note 5.
(4)	Represents securities purchased with cash collateral received for securities on loan.
(5)	The rate shown reflects the seven-day yield as of January 31, 2024.

Schedule of Investments - Virtus LifeSci Biotech Clinical Trials ETF (continued)

January 31, 2024 (unaudited)

Fair Value Measurements

The Fund utilizes a fair value hierarchy which prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. Level 1 includes unadjusted quoted prices in active markets for identical assets or liabilities that the Fund has the ability to access. Level 2 includes observable inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly. These inputs may include quoted prices for the identical instrument on an inactive market, prices for similar securities, interest rates, prepayment speeds, credit risk, yield curves, default rates and similar data. Level 3 includes unobservable inputs for the asset or liability, to the extent relevant observable inputs are not available; representing the Fund's own assumptions about the assumptions a market participant would use in valuing the asset or liability, and would be based on the best information available. The inputs or methodology used for valuing securities are not necessarily an indication of the risk associated with investing in those securities.

The following table summarizes valuation of the Fund’s investments under the fair value hierarchy levels as of January 31, 2024.

	Level 1		Level 2		Level 3		Total
Asset Valuation Inputs
Common Stocks	$	9,880,825	$	27,475	$	—	$	9,908,300
Money Market Fund		733,438		—		—		733,438
Total	$	10,614,263	$	27,475	$	—	$	10,641,738

ETFIS Series Trust I (PFFR) NPORT-PVirtus LifeSci Biotech Clinical Trials ETF (Jan 2024 report)